These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 7592913

  • 1. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
    Lerner EC, Qian Y, Hamilton AD, Sebti SM.
    J Biol Chem; 1995 Nov 10; 270(45):26770-3. PubMed ID: 7592913
    [Abstract] [Full Text] [Related]

  • 2. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
    Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM.
    J Biol Chem; 1995 Nov 10; 270(45):26802-6. PubMed ID: 7592920
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 10; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 4. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 10; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 5. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
    Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM.
    Cancer Res; 1999 Oct 01; 59(19):4919-26. PubMed ID: 10519405
    [Abstract] [Full Text] [Related]

  • 6. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
    Fiordalisi JJ, Johnson RL, Weinbaum CA, Sakabe K, Chen Z, Casey PJ, Cox AD.
    J Biol Chem; 2003 Oct 24; 278(43):41718-27. PubMed ID: 12882980
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 8. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.
    Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM.
    J Biol Chem; 1995 Jan 13; 270(2):660-4. PubMed ID: 7822292
    [Abstract] [Full Text] [Related]

  • 9. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW.
    Br J Haematol; 2005 Sep 13; 130(6):912-25. PubMed ID: 16156861
    [Abstract] [Full Text] [Related]

  • 10. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I.
    Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang R, Bishop WR.
    J Biol Chem; 1997 Apr 11; 272(15):10232-9. PubMed ID: 9092572
    [Abstract] [Full Text] [Related]

  • 11. CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase.
    McGuire TF, Qian Y, Blaskovich MA, Fossum RD, Sun J, Marlowe T, Corey SJ, Wathen SP, Vogt A, Hamilton AD.
    Biochem Biophys Res Commun; 1995 Sep 05; 214(1):295-303. PubMed ID: 7669049
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1beta in vascular smooth muscle cells.
    Finder JD, Litz JL, Blaskovich MA, McGuire TF, Qian Y, Hamilton AD, Davies P, Sebti SM.
    J Biol Chem; 1997 May 23; 272(21):13484-8. PubMed ID: 9153192
    [Abstract] [Full Text] [Related]

  • 13. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
    Mazet JL, Padieu M, Osman H, Maume G, Mailliet P, Dereu N, Hamilton AD, Lavelle F, Sebti SM, Maume BF.
    FEBS Lett; 1999 Oct 29; 460(2):235-40. PubMed ID: 10544242
    [Abstract] [Full Text] [Related]

  • 14. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Cancer Res; 1995 Oct 01; 55(19):4243-7. PubMed ID: 7671229
    [Abstract] [Full Text] [Related]

  • 15. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation.
    McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM.
    J Biol Chem; 1996 Nov 01; 271(44):27402-7. PubMed ID: 8910319
    [Abstract] [Full Text] [Related]

  • 16. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
    Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B, Hamilton AD, Sebti SM.
    Cancer Res; 2003 Dec 15; 63(24):8922-9. PubMed ID: 14695209
    [Abstract] [Full Text] [Related]

  • 17. Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
    Kusama T, Mukai M, Tatsuta M, Matsumoto Y, Nakamura H, Inoue M.
    Clin Exp Metastasis; 2003 Dec 15; 20(6):561-7. PubMed ID: 14598891
    [Abstract] [Full Text] [Related]

  • 18. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts.
    Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM.
    Oncogene; 1996 Nov 07; 13(9):1991-9. PubMed ID: 8934546
    [Abstract] [Full Text] [Related]

  • 19. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity.
    Peterson YK, Kelly P, Weinbaum CA, Casey PJ.
    J Biol Chem; 2006 May 05; 281(18):12445-50. PubMed ID: 16517596
    [Abstract] [Full Text] [Related]

  • 20. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.
    James GL, Goldstein JL, Brown MS.
    J Biol Chem; 1995 Mar 17; 270(11):6221-6. PubMed ID: 7890759
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.